U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093970) titled 'A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors' on July 22.
Brief Summary: The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.
Study Start Date: July 24, 2024
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: MRG006A
Administrated intravenously
Recruitment Status: RECRUITING
Sponsor: Shanghai Miracogen Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....